A double-blind comparison of meglumine iodamide and Renografin 60 (52% meglumine diatrizoate and 8% sodium diatrizoate) for bolus excretory urography was performed. Doses of 0.8 cc/kg. to a maximum of 55 cc were administered to fifty patients, twenty-five receiving each drug.
INTRODUCTION
lodamide is a new contrast agent for excretory urography which is used in Europe but has not as yet been approved for use in the United States. It is a triiodinated benzoic acid derivative differing from diatrizoate by the substitution of a -CONHCH3 in position three of the benzoic ring for the acetyl-amino radical of the diatrizoate (Fig. 1) . Extensive animal studies of the pharmacology and toxicity of iodamide have shown it to be similar to the standard contrast agents now used for urography [1] . The purpose of the present study was to conduct a double-blind comparison of the side-effects and the quality of the urograms following bolus injection of meglumine iodamide and Renografin 60 (meglumine diatrizoate 52% and sodium diatrizoate 8%).
Materials and Methods
Bolus excretory urograms were performed in fifty consecutive adult out-patients referred for this examination. Excluded from this group were patients who were pregnant, had a history of hypersensitivity to contrast agents or iodine compounds, had received a cholecystocholangiographic agent within one month of the study, had severely impaired renal function (less than 10 mm per minute creatinine clearance and/or 50% elevation above normal of both BUN and serum creatinine), had impaired liver function (serum bilirubin above 3 mg %), or had a history of cardiovascular disease or electrocardiographic abnormalities prior to enrollment. In addition, moribund patients and those with hyperthyroidism, homozygous sickle cell disease, pheochromocytoma and multiple myeloma were not included in the study. All patients received complete physical examinations before the study and 24 and 72 hours after it. At these times, blood was also drawn for CBC, serum creatinine, SGOT, and SMA-12, and a urinalysis was performed. Any abnormalities after 72 hours were followed at weekly intervals until a return to normal. Complete 12 lead electrocardiograms were done before, during, and after the injection on twenty-four of these patients. All patients had an initial opthalmologic evaluation and ten of these patients had an ophthalmologic examination six months later. The contrast agents were packaged in vials, labelled in code. Twenty-five vials contained 55 cc of 65% meglumine iodamide containing the equivalent of 300 mg per ml of organicallybound iodides, and, therefore, 15 grams of iodine. Twenty-five vials contained 50 cc of Renografin 60, which had the equivalent of 288 mg per ml or organically-bound iodide, and therefore, 14.4 grams of iodine. The drugs were administered in a double-blind manner. Individual doses were calculated on the basis of 0.8 ml/kg body weight with a maximum dose of 55 cc. After a preliminary film had been obtained, the contrast was injected as a bolus (injection time of ½/2-1 minute). Films were obtained at one, three, five, ten, twenty and thirty minutes after completion of injection and additional radiographs at later intervals were obtained as indicated. Each film was evaluated as to technical adequacy by a radiologist who was unaware of the agent used. In those films judged adequate, the radiographic density of nephrogram, calices, pelvis, ureter, and bladder was graded from 0 representing no opacification, to 2 representing dense opacification. Three different uroradiologists each graded one-third of the cases on a random basis.
Results
Drugs were administered in a double-blind manner: meglumine iodamide was given to eighteen males and seven females ranging in age from 23 to 74 years (average 51.5 years); Renografin 60 was given to fifteen males and ten females ranging in age from 18 to 77 years (average 45.6 years). The total doses in the meglumine iodamide group ranged from 37 to 50 ml (average 48.7 ml) while those in the Renografin 60 group ranged from 30.9 to 50 ml (average 48 ml).
The overall performance of the contrast agent was judged "satisfactory" in twentythree of the twenty-five patients receiving each agent. A radiologic diagnosis was possible in twenty-four of the twenty-five patients in each group; in each case in which a radiologic diagnosis was not possible the drug performance had also been graded "unsatisfactory." Of the twenty-five patients who received meglumine iodamide, ten had normal excretory urograms. The other fifteen patients had genitourinary tract conditions which were diagnosed as renal calculi, ureteric obstructions, prostatic enlargement, hydronephrosis and trabeculated bladder. Of the twenty-five patients who received Renografin 60, fifteen had normal excretory urograms. The other twelve had genitourinary tract conditions which were diagnosed as renal calculi, renal and ureteric displacement, nephrectomy, caliectasis, renal scarring and prostatic enlargement.
Laboratory abnormalities for each group are listed in Table 1 . It should be noted that abnormalities in a given test were counted separately each time they occurred. Of the twenty-five patients treated with meglumine iodamide, thirteen patients had a total of twenty-seven laboratory abnormalities. Of the twenty-five patients treated with Renografin 60, ten had a total of twenty-two abnormalities. Adverse reactions were comparable in frequency, severity, and nature for the two drug groups. Among the twenty-five patients given the meglumine iodamide, three males and three females representing a total of six patients had eight adverse reactions: two patients developed both pruritus and urticaria, two developed nausea and vomiting, one patient had nausea and one patient had a decrease in blood pressure. The patient with a drop in blood pressure had a control value of 107/50 and had a drop in blood pressure to 80/20 at 30 minutes after injection. The patient was treated with Ringer's lactate solution and returned to a control blood pressure within the hour.
Of the twenty-five patients who received Renografin 60, six (three males and three females) had a total of six adverse reactions: nausea and vomiting in one patient, nausea in one, vomiting in two, blood pressure increase in one, and blood pressure decrease requiring no treatment in one.
The electrocardiograms done before, during, and ten minutes after the injection of eleven patients given meglumine iodamide and thirteen patients given Renografin 60 showed no significant abnormalities at any time for either group of patients. Ophthalmologic examinations were done for fifty patients at the time of treatment and for ten of the fifty patients approximately six months later. These studies showed abnormalities in five patients at the time of treatment with no change in any patient at six months. The degree of opacification produced in each site for each drug is shown in Table 2 . The denser of bilateral sites was chosen for statistical analysis in this table. As can be seen from the table, every patient did not have a film at each time due to individual modifications necessary for diagnostic accuracy. In Table 3 the time to first dense opacification is shown for the seventeen patients who received meglumine iodamide and the eleven patients who received Renografin 60 and who also had every required film. For the purpose of statistical analysis each of the two paired structures was treated as a separate entity in Table 3 . In addition, those patients who did not have dense opacification at any time in a given portion of the urinary tract were not included in that portion of the statistical analysis.
In assessing the results presented in Tables 2 and 3 , the Wilcoxan model of nominal-ordinal association was used. Inference was calculated by the application of the Mann-Whitney U-Test [2] in order to determine whether knowledge of the radiopaque material could predict the degree of denseness of the image (Table 2) or the time to first dense opacification (Table 3) . In Table 2 , at all sites in which there was a significant difference in the opacification (at varying P values as shown) produced by the two drugs, iodamide produced the better results. Similarly in Table  3 , meglumine iodamide produced a statistically significant (at varying P values as shown) earlier first dense opacification of all sites except parenchyma. Note: At all sites except for the parenchyma there is a statistically significant earlier first dense opacification with iodamide (I = iodamide, R = Renografin 60).
DISCUSSION
In our study the side-effects of iodamide were comparable to those of Renografin. This result is similar to that of deLange and Hermans, who compared side-effects of iodamide and diatrizoate in excretory urography in 1,418 patients [3] . They used a dose comparable to ours and found some kind of side-effect in 20% of the patients who received each agent. They found no correlation with sex or age of the patient. Other studies of iodamide have found a variable incidence of adverse reaction [4, 5, 6] but none of these represented a comparative trial with another agent.
The data of our clinical trial indicates that the two agents are equal for parenchymal opacification but that iodamide is superior for opacifying the calices and pelvis. For the ureters and bladder, there is a clear trend towards superior performance by iodamide but not with the same degree of statistical confidence as was demonstrated for the calices and pelvis.
The standard contrast agents such as Renografin 60 which was used in this study are excreted by the normal kidney almost if not entirely by glomerular filtration. Tubular secretion does not play a significant role [7] . Work in both animals [8] and humans [9] has suggested that, in contrast, iodamide may also be secreted by a normal kidney by tubular secretion. The data in Tables 2 and 3 of our study suggest that iodamide is superior to diatrizoate both in the degree of opacification and in the time of earliest dense opacification. If tubular secretion occurs with iodamide but does not occur with diatrizoate, a rapid elimination and denser opacification would be expected for iodamide.
